Bausch Health Companies Inc. (TSX: BHC)

Market Cap	3.56B
Revenue (ttm)	12.26B
Net Income (ttm)	-622.06M
Shares Out	360.99M
EPS (ttm)	-1.70
PE Ratio	n/a
Forward PE	2.43
Dividend	n/a
Ex-Dividend Date	n/a

Volume	326,406
Open	9.62
Previous Close	9.54
Day's Range	n/a
52-Week Range	8.32 - 15.43
Beta	0.83
Analysts	n/a
Price Target	13.35 (+37.63%)
Earnings Date	Aug 1, 2024

About Bausch Health Companies

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Thomas J. Appio
• Employees: 20,270
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: BHC

Financial Performance

In 2023, BHC's revenue was $8.76 billion, an increase of 7.79% compared to the previous year's $8.12 billion. Losses were -$592.00 million, 179.2% more than in 2022.

Financial numbers in USD